Cibus, Inc. provided impairment charges guidance for the year ended December 31, 2023. As a result of the Company?s annual impairment analysis, the management of the company has determined that its goodwill and in-process R&D indefinite-lived intangible assets were impaired by an estimated $150.4 million and an estimated $99.0 million, respectively, for the year ended December 31, 2023. Accordingly, management expects to record a non-cash impairment charge of an estimated approximately $249.4 million for impairment of goodwill and in-process R&D indefinite-lived intangible assets in the consolidated financial statements for the year ended December 31, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.59 USD | -.--% | +2.93% | -10.44% |
May. 09 | Cibus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 09 | Transcript : Cibus, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.44% | 384M | |
+11.29% | 226B | |
+8.76% | 188B | |
+12.90% | 137B | |
+25.95% | 108B | |
+0.34% | 63.19B | |
+11.08% | 52.26B | |
+5.62% | 51B | |
+6.28% | 43.89B | |
+4.80% | 38.07B |
- Stock Market
- Equities
- CLXT Stock
- News CALYXTPAR
- Cibus, Inc. Provides Impairment Charges Guidance for the Year Ended December 31, 2023